GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXIBF) » Definitions » EPS without NRI

WXIBF (WuXi Biologics (Cayman)) EPS without NRI : $0.13 (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) EPS without NRI?

WuXi Biologics (Cayman)'s earnings per share without non-recurring items for the six months ended in Jun. 2024 was $0.07. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was $0.13.

During the past 12 months, WuXi Biologics (Cayman)'s average earnings per share (NRI) Growth Rate was -19.20% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 33.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 45.10% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for WuXi Biologics (Cayman)'s EPS without NRI or its related term are showing as below:

WXIBF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 33.6   Med: 57.2   Max: 138.1
Current: 33.6

During the past 10 years, WuXi Biologics (Cayman)'s highest 3-Year average Earnings Per Share (NRI) Growth Rate was 138.10% per year. The lowest was 33.60% per year. And the median was 57.20% per year.

WXIBF's 3-Year EPS without NRI Growth Rate is ranked better than
81.43% of 1244 companies
in the Biotechnology industry
Industry Median: 4.85 vs WXIBF: 33.60

WuXi Biologics (Cayman)'s EPS (Diluted) for the six months ended in Jun. 2024 was $0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.08.

WuXi Biologics (Cayman)'s EPS (Basic) for the six months ended in Jun. 2024 was $0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.09.


WuXi Biologics (Cayman) EPS without NRI Historical Data

The historical data trend for WuXi Biologics (Cayman)'s EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) EPS without NRI Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.06 0.12 0.16 0.15

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.07 0.09 0.06 0.07

Competitive Comparison of WuXi Biologics (Cayman)'s EPS without NRI

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s PE Ratio without NRI falls into.



WuXi Biologics (Cayman) EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi Biologics (Cayman)  (OTCPK:WXIBF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


WuXi Biologics (Cayman) EPS without NRI Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) Business Description

Traded in Other Exchanges
Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.